🧬 Carboplatin Dose Calculator
Clinical Tool Using Calvert Formula | Version 1.0.0 | October 2025
This calculator is for healthcare professionals only. Results must be verified with institutional protocols. The calculated dose should be reviewed by a qualified oncology pharmacist or physician before administration. This tool does not replace clinical judgment.
Patient Parameters
Calculation Trace
Clinical Interpretation
GFR vs Dose Curve
Calculation History
No calculations logged yet.
Clinical Dosing Guidelines
Common AUC Targets by Cancer Type
| Cancer Type | Typical AUC | Notes |
|---|---|---|
| Ovarian Cancer | AUC 5-6 | Often AUC 5 in combination with paclitaxel |
| Non-Small Cell Lung Cancer | AUC 5-6 | Often AUC 6 in combination regimens |
| Small Cell Lung Cancer | AUC 5-6 | In combination with etoposide |
| Bladder Cancer | AUC 4.5-5 | Adjuvant or metastatic settings |
| Testicular Cancer | AUC 5-7 | Salvage therapy |
The Calvert Formula
Developed by Calvert et al. (1989), this formula individualizes carboplatin dosing based on renal function to achieve a target area under the curve (AUC).
GFR Calculation Methods
Cockcroft-Gault (Standard)
CrCl (male) = [(140 - age) × weight (kg)] / (72 × SCr [mg/dL])
CrCl (female) = CrCl (male) × 0.85
Most commonly used for carboplatin dosing. Capping at 125 mL/min is recommended.
CKD-EPI
More accurate in patients with normal/near-normal renal function. Requires de-indexing from BSA for carboplatin dosing.
MDRD
Less accurate at higher GFR ranges. Generally not preferred for chemotherapy dosing.
Note: Original MDRD included a race-based correction factor (×1.212 for African American patients). This calculator does not include race-based adjustments due to growing evidence that race-based corrections perpetuate health inequities and lack biological basis. Clinicians should be aware of this limitation.
Safety Considerations
- Pre-treatment Requirements: Adequate hydration, baseline CBC with differential, baseline renal function, verification of no prior hypersensitivity
- Maximum single dose typically should not exceed 750 mg (toxicity risk without benefit)
- Dose reduction required if baseline myelosuppression present (ANC <1500, platelets <100,000) 1500,>
- Monitor CBC with differential before each cycle and at nadir (typically day 21)
- Avoid in patients on dialysis without specialized dosing protocols
- GFR < 20 mL/min requires dose reduction of 25-50% or alternative therapy
- Risk of severe thrombocytopenia and neutropenia increases significantly with AUC > 7
- For obese patients (BMI >30), consider adjusted body weight to prevent overdosing
- Renal function should be assessed before each cycle; adjust dose if GFR decreases
References
- Calvert AH, et al. J Clin Oncol. 1989;7(11):1748-1756.
- NCCN Clinical Practice Guidelines in Oncology - Ovarian Cancer (2025)
- Ekhart C, et al. Br J Clin Pharmacol. 2006;62(1):45-53.
- Cockroft DW, Gault MH. Nephron. 1976;16(1):31-41.
What is Carboplatin?
Carboplatin is a platinum-based chemotherapy drug used to treat various cancers including ovarian, lung, bladder, and testicular cancers. Unlike many chemotherapy drugs that are dosed based on body surface area (BSA), carboplatin dosing is uniquely calculated using the Calvert formula, which takes into account kidney function to achieve a target drug exposure level.
Too much carboplatin can cause severe side effects like bone marrow suppression and kidney damage. Too little may not effectively treat the cancer. The Calvert formula helps oncologists find the “just right” dose for each patient.
Common Uses of Carboplatin
- Ovarian Cancer: Often combined with paclitaxel (AUC 5-6)
- Lung Cancer: Both small cell and non-small cell types (AUC 5-6)
- Bladder Cancer: Adjuvant or metastatic settings (AUC 4.5-5)
- Testicular Cancer: Salvage therapy (AUC 5-7)
Understanding the Calvert Formula
The Calvert formula, developed in 1989, revolutionized carboplatin dosing by incorporating kidney function directly into the calculation.
Formula Components
| Component | Description | Typical Values |
|---|---|---|
| Target AUC | Desired drug exposure level | 4-7 mg/mL/min (cancer-specific) |
| GFR | Glomerular Filtration Rate (kidney function) | Normal: 90-120 mL/min |
| +25 | Non-renal clearance of carboplatin | Constant value |
What is AUC?
AUC (Area Under the Curve) measures the total drug exposure over time. Think of it like measuring how much medication stays in the bloodstream. Higher AUC means more drug exposure, which can be more effective but also more toxic.
| Cancer Type | Typical AUC | Notes |
|---|---|---|
| Ovarian Cancer | AUC 5-6 | Often AUC 5 with paclitaxel |
| Lung Cancer (NSCLC) | AUC 5-6 | Combination regimens |
| Small Cell Lung | AUC 5-6 | With etoposide |
| Bladder Cancer | AUC 4.5-5 | Adjuvant or metastatic |
| Testicular Cancer | AUC 5-7 | Salvage therapy |
GFR Calculation Methods
Since kidney function (GFR) is crucial for carboplatin dosing, our calculator offers three validated methods to estimate GFR:
1. Cockcroft-Gault Formula
For Females: CrCl = [(140 – age) × weight (kg)] / (72 × serum creatinine) × 0.85
Best for: Most commonly used for carboplatin dosing. Works well for standard patients.
Limitation: Less accurate in very obese or very thin patients.
2. CKD-EPI Formula (2021)
Where: κ = 0.9 (males) or 0.7 (females)
α = -0.302 (males) or -0.241 (females)
Best for: Patients with normal or near-normal kidney function. More accurate than Cockcroft-Gault in some populations.
Note: Must be de-indexed (adjusted) from the standard value for carboplatin dosing.
3. MDRD Formula
Best for: Patients with chronic kidney disease.
Limitation: Less accurate at higher GFR ranges, so generally not preferred for chemotherapy dosing.
How to Use the Calculator
Follow these simple steps to calculate the correct carboplatin dose:
1Enter Patient Information
- Age: Patient’s current age in years
- Sex: Male or Female (affects GFR calculation)
- Weight: Current body weight in kilograms
- Height: Height in centimeters (optional, used for CKD-EPI method)
2Enter Kidney Function Data
- Serum Creatinine: Latest lab value in mg/dL or µmol/L
- Choose Unit: Select mg/dL or µmol/L (calculator converts automatically)
3Select Calculation Settings
- Target AUC: Based on cancer type and protocol (typically 4-6)
- GFR Method: Choose Cockcroft-Gault (most common), CKD-EPI, or MDRD
- GFR Capping: Enable to cap at 125 mL/min (recommended)
- Dose Rounding: Round to nearest 1, 5, 10, 25, or 50 mg
4Review Results
The calculator provides:
- Recommended carboplatin dose in milligrams
- Calculated GFR value and method used
- Step-by-step calculation breakdown
- Clinical warnings for renal impairment or unusual values
- Monitoring recommendations
Key Features
🎯 Multiple GFR Methods
Choose from Cockcroft-Gault, CKD-EPI 2021, or MDRD based on patient characteristics.
📊 Detailed Calculation Trace
See every step of the calculation with formulas, intermediate values, and final results.
⚠️ Clinical Warnings
Automatic alerts for renal impairment, unusual doses, and safety considerations.
💾 Calculation History
Save and review previous calculations with timestamps for patient records.
🖨️ Print-Ready Results
Generate professional printouts for medical charts and documentation.
🔒 Privacy First
All calculations done in your browser. No data sent to servers.
Clinical Example
Case: 65-year-old woman with ovarian cancer
| Parameter | Value |
|---|---|
| Age | 65 years |
| Sex | Female |
| Weight | 70 kg |
| Height | 165 cm |
| Serum Creatinine | 0.9 mg/dL |
| Target AUC | 5 mg/mL/min |
Calculation Steps:
- Calculate GFR using Cockcroft-Gault:
CrCl = [(140 – 65) × 70] / (72 × 0.9) × 0.85 = 81.3 mL/min - Apply Calvert Formula:
Dose = 5 × (81.3 + 25) = 5 × 106.3 = 531.5 mg - Round to nearest 10 mg:
Final Dose = 530 mg
Safety Considerations & Warnings
When to Use Caution
- Mild (GFR 45-59): Monitor closely, standard dosing usually safe
- Moderate (GFR 30-44): Consider 10-25% dose reduction
- Severe (GFR 15-29): Requires significant dose reduction
- Kidney Failure (GFR <15): Carboplatin may be contraindicated 15):
Special Populations
- Elderly Patients: Higher risk of toxicity due to age-related kidney decline
- Low Body Weight: May need dose adjustments for patients under 50 kg
- Obese Patients: Consider actual vs. ideal body weight for calculations
- Dialysis Patients: Requires specialized dosing protocols not covered by standard calculators
Required Monitoring
- Complete blood count (CBC) before each cycle
- Serum creatinine and kidney function tests
- Nadir monitoring (lowest blood count, typically day 21)
- Watch for: fever, bleeding, unusual bruising, fatigue
Frequently Asked Questions
⚠️ Medical Disclaimer
For Healthcare Professionals Only: This calculator is intended as a clinical decision support tool for qualified healthcare professionals, including physicians, pharmacists, and oncology nurses.
Not a Substitute for Clinical Judgment: The results provided by this calculator should not replace professional medical judgment, clinical experience, or consultation with oncology specialists. Always verify calculations and consider individual patient factors.
Accuracy Not Guaranteed: While we strive for accuracy, this tool is provided “as is” without warranties. Users are responsible for verifying all calculations and dosing decisions. The developers assume no liability for errors, omissions, or adverse outcomes.
Institutional Protocols: Always follow your institution’s carboplatin dosing protocols and guidelines. This calculator provides general guidance that may differ from local practices.
Patient Safety: Always perform independent dose verification, obtain appropriate laboratory tests, and monitor patients according to established oncology standards of care.
No Medical Advice: This tool does not provide medical advice, diagnosis, or treatment recommendations. For medical questions, consult qualified healthcare providers.
Last Updated: October 2025 | Based on Calvert et al. (1989) formula and current CKD-EPI 2021 guidelines